Published in Br J Clin Pharmacol on April 10, 2007
Dark Chocolate and Platelet Function in Humans | NCT01099150
Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci (2013) 0.99
Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One (2010) 0.98
Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases. PLoS One (2012) 0.97
Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation. Evid Based Complement Alternat Med (2012) 0.88
Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets. Br J Pharmacol (2009) 0.85
Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs. Cardiovasc Res (2012) 0.82
Pentamethylquercetin (PMQ) reduces thrombus formation by inhibiting platelet function. Sci Rep (2015) 0.77
Effects of apigenin on steroidogenesis and steroidogenic acute regulatory gene expression in mouse Leydig cells. J Nutr Biochem (2011) 0.77
Revisiting the mechanistic basis of the French Paradox: Red wine inhibits the activity of protein disulfide isomerase in vitro. Thromb Res (2015) 0.75
Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem (1987) 10.61
The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev (2000) 8.92
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Preparation of suspensions of washed platelets from humans. Br J Haematol (1972) 4.02
Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr (2005) 4.01
Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med (2004) 3.76
Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci (2004) 2.47
Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (1991) 2.26
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation (2001) 1.90
Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol (2004) 1.88
Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood (2005) 1.86
Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem (1994) 1.46
Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest (1998) 1.46
Cell signaling pathways altered by natural chemopreventive agents. Mutat Res (2004) 1.23
Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol (1984) 1.22
Cell signalling through thromboxane A2 receptors. Cell Signal (2004) 1.20
Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. Annu Rev Nutr (2004) 1.15
Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta (1998) 1.12
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci (2005) 1.09
Thromboxane A2: its generation and role in platelet activation. Prog Lipid Res (1989) 1.09
Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost (2005) 1.08
Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem (1999) 1.07
Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost (2003) 1.04
The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr (2000) 1.03
Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost (2005) 1.03
Inhibition of platelet aggregation by some flavonoids. Thromb Res (1991) 0.94
Inhibitory effects of sulphated flavonoids isolated from Flaveria bidentis on platelet aggregation. Thromb Res (2004) 0.90
Aspirin resistance. J Thromb Haemost (2005) 0.89
Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett (2004) 0.89
Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem (2004) 0.88
Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol Pharmacol (1991) 0.88
Role of the ERK pathway in the activation of store-mediated calcium entry in human platelets. J Biol Chem (2001) 0.87
Dietary components and human platelet activity. Platelets (2002) 0.86
Rapid measurements of intracellular calcium using a fluorescence plate reader. Biotechniques (1999) 0.86
Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc Pharmacol (2002) 0.86
Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids (2004) 0.85
Flavanols and platelet reactivity. Clin Dev Immunol (2005) 0.84
Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis. J Thromb Haemost (2003) 0.83
The role of N-glycosylation of human thromboxane A2 receptor in ligand binding. Arch Biochem Biophys (1998) 0.82
The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase. Prostaglandins Leukot Essent Fatty Acids (1993) 0.81
Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F(2alpha) and the thromboxane mimetic U46619. J Endocrinol (2006) 0.80
Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. Eur J Biochem (1999) 0.80
Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol (2003) 0.78
Flavonoid-mediated inhibition of actin polymerization in cold-activated platelets. Platelets (2005) 0.77
Genistein and daidzein modulate in vitro rat uterine contractile activity. J Steroid Biochem Mol Biol (2000) 0.77
Thromboxane receptor signalling in human myometrial cells. Prostaglandins Other Lipid Mediat (2002) 0.77
Diet and aging: bearing on thrombosis and hemostasis. Semin Thromb Hemost (2005) 0.76
Extracellular disulfide exchange and the regulation of cellular function. Antioxid Redox Signal (2006) 2.16
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica (2009) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circ Res (2004) 1.61
Platelet PECAM-1 inhibits thrombus formation in vivo. Blood (2005) 1.53
Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med (2011) 1.49
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Staphylococcal extracellular adherence protein induces platelet activation by stimulation of thiol isomerases. Arterioscler Thromb Vasc Biol (2012) 1.45
A role for the thiol isomerase protein ERP5 in platelet function. Blood (2004) 1.41
Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood (2002) 1.36
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem (2010) 1.29
Platelets release novel thiol isomerase enzymes which are recruited to the cell surface following activation. Br J Haematol (2009) 1.21
In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A (2007) 1.20
Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood (2013) 1.15
[Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev Esp Cardiol (2007) 1.13
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood (2008) 1.09
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Rev Esp Cardiol (2004) 1.08
Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett (2003) 1.06
Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood (2007) 1.05
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr (2006) 1.03
Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer (2004) 1.03
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol (2006) 1.03
Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfus Apher Sci (2007) 1.02
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem (2004) 1.01
Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem (2002) 1.01
Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation (2012) 0.99
Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One (2010) 0.98
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol (2005) 0.98
LXR as a novel antithrombotic target. Blood (2011) 0.97
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharmacol (2010) 0.96
Identification of cellular proteins modified in response to African swine fever virus infection by proteomics. Proteomics (2004) 0.95
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Thrombosis as a conformational disease. Haematologica (2005) 0.93
Tachykinins regulate the function of platelets. Blood (2004) 0.93
Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica (2011) 0.93
Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica (2005) 0.93
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood (2007) 0.92
Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol (2007) 0.92
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res (2008) 0.92
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood (2007) 0.92
Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood (2012) 0.92
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest (2008) 0.92
Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. Haematologica (2009) 0.91
L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica (2010) 0.91
Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica (2010) 0.90
"Open rather than closed" malonate methano-fullerene derivatives. The formation of methanofulleroid adducts of Y3N@C80. J Am Chem Soc (2007) 0.90
Purification and functional characterisation of rhiminopeptidase A, a novel aminopeptidase from the venom of Bitis gabonica rhinoceros. PLoS Negl Trop Dis (2010) 0.90
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. Am Heart J (2004) 0.90
Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol (2010) 0.90
Endogenous inhibitory mechanisms and the regulation of platelet function. Methods Mol Biol (2012) 0.89
Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiat Prot Dosimetry (2007) 0.89
Snakebite and its socio-economic impact on the rural population of Tamil Nadu, India. PLoS One (2013) 0.88
Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation (2004) 0.88
Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J (2010) 0.88
Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation. Breast Cancer Res Treat (2003) 0.88
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) (2012) 0.87
Treatment of the open abdomen with topical negative pressure therapy: a retrospective study of 46 cases. Int Wound J (2011) 0.87
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost (2014) 0.86
JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Ann Hematol (2008) 0.86
Structure of the snake-venom toxin convulxin. Acta Crystallogr D Biol Crystallogr (2003) 0.86
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica (2007) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86
Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res (2012) 0.86